Clinical trial
A Double-Blind, Placebo-Controlled, Dose-Titration Study to Determine Safety, Tolerability and Preliminary Efficacy of RWJ-333369 as Adjunctive Therapy in Subjects With Treatment-Resistant Partial Seizures (With or Without Secondary Generalization) or Primarily Generalized Tonic-Clonic Seizures
NCT00210652 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled, Dose-Titration Study to Determine Safety, Tolerability and Preliminary Efficacy of RWJ-333369 as Adjunctive Therapy in Subjects With Treatment-Resistant Partial Seizures (With or Without Secondary Generalization) or Primarily Generalized Tonic-Clonic Seizures
- Lead sponsor
- SK Life Science, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2004
- Completion date
- March 31, 2010
- Enrollment
- 47 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.